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P rogn ostic  F actors in A llogen eic  B one M arrow  
T ran sp lan tation  for M u ltip le  M yelom a
By Gosta Gahrton, Santé Tuîü, Per Ljungman. Joan Biadé, Lena Brandt, Michele Cavo, Thierry Façon, Alois Gratwohl, 
Anton Hagenbeek, Peter Jacobs, Antonio de Laurenzî, M. Van Lint, Mauricette Michallet, Jukka Nikoskelainen,
Josy Reiffers, Diana Sarnson, Léo Verdonck, Théo de Witte, and Lüsa Volin
Purpose: To analyze prognostic factors for allogeneic 
bone marrow transplantation (BMT) in multiple my­
eloma.
Patients and Methods: One hundred sixty-two re- 
ports of allogeneic matched sibling-donor transplants in 
multiple myeloma received by the European Group for 
Blood and Marrow Transplantation (EBMT) registry be­
tween 1983 and early 1993 were analyzed for prognos­
tic factors. End points were complete remission, survival, 
and duration of complete remission.
Results: Following BMT, 44% of all patients and 60% 
of assessable patients entered complete remission. The 
overall actuarial survival rate was 32% at 4 years and 
28% at 7 years. The overall relapse-free survival rate of 
72 patients who were in complete remission after BMT 
was 34% at 6 years. Favorable pretransplant prognostic
factors for survival were female sex (41% at 4 years), 
stage I disease at diagnosis (52% at 4 years), one line 
of previous treatment (42% at 4 years), and being in 
complete remission before conditioning (64% at 3 years). 
The subtype immunoglobulin A (IgA) myeloma and a low 
/?2~rnicroglobulin level (< 4 g/L) also tended to have a 
favorable prognostic impact. The most important post­
transplant prognostic factor was to enter a complete re­
mission. Grade III to IV graft-versus-host disease (GVHD) 
was associated with poor survival.
Conclusion: Patients with a low tumor burden who 
respond to Treatment before BMT and are transplanted 
after first-line therapy have the best prognosis following 
BMT.
J Clin Oncol 13:1312-1322. © 1995 by American So­
ciety of Clinical Oncology.
MULTIPLE MYELOMA is a malignant disorder with a median survival duration of less than 3 
years after conventional chemotherapy.1-3 However, sur­
vival is highly variable. Some patients die within months, 
while occasional patients survive more than 10 years. 
This heterogeneity in the prognosis of multiple myeloma 
has encouraged studies of prognostic variables. A high 
tumor burden, high C~reactive protein level, high plasma­
cell thymidine-labeling index, elevated /^-microglobulin 
level, low serum albumin level, and low platelet count 
have been associated with extremely poor survival fol­
lowing conventional chemotherapy.4'8 Therefore, such 
variables have been used to select patients for more inten­
sive treatment. However, only a few studies have at­
tempted to delineate prognostic factors of importance for 
the outcome of patients treated with high-dose chemo­
therapy followed by either autologous bone marrow trans­
plantation (ABMT)9,10 or allogeneic bone marrow trans-
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plantation (BMT).11 In a previous study by the European 
Group for Blood and Marrow Transplantation (EBMT) 
of 90 patients with multiple myeloma who underwent 
BMT, a number of factors were found to influence long­
term survival, including stage I disease at diagnosis, being 
in complete remission at transplantation, and having re­
ceived only a few lines of treatment pretransplant.11 The 
first patients reported to the EBMT registry in 1983 have 
now been monitored for up to 10 years. In the present 
updated report of 162 patients in the EBMT registry, new 
variables of prognostic importance have been found.
PATIENTS AND METHODS
Patients
One hundred sixty-two patients with multiple myeloma who re­
ceived a bone marrow graft from an human leukocyte antigen 
(HLA)-compatible sibling donor between 1983 and early 1993 were 
reported to the EBMT registry; 92 were men and 70 were women. 
The median age was 43 years (range, 23 to 59). The myeloma 
subtype was immunoglobulin G (IgG) in 80 patients, IgA in 33, 
light chain in 31, and IgD in two. Five patients had nonsecretory 
multiple myeloma, and three had plasma-cell leukemia. The reports 
were incomplete in eight patients.
At diagnosis, 22 patients were in stage I, 30 in stage II (one IIB), 
and 109 in stage III (23 IIIB); stage was not reported in one patient. 
The median time from diagnosis to BMT was 14 months (range, 3 
to 168).
Treatment Before BMT
Treatment before BMT varied according to center. Forty-one pa­
tients received conventional therapy with intermittent melphalan plus 
prednisolone as first-line treatment and 121 patients received other 
drug combinations, most of which contained melphalan or cyclo-
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phosphamide in addition to other drugs. Thirty-six different combi­
nations of drugs were used for second-line treatment and 21 combi­
nations were used for subsequent treatment modalities. Twenty-six 
patients entered complété remission (defined as the absence of de­
tectable monoclonal Igs in serum and of detectable free light chains 
in urine on either conventional Immunoelectrophoresis or immu- 
nofixation, as well as the absence of apparent myeloma cells in the 
marrow on conventional cytologic analysis) after first-line treatment. 
Sixty-seven patients had a partial remission (defined as a decrease 
of serum I g levels to a concentration less than 50% of pre treatment 
value, decrease in urine light-chain excretion to <  0.2 g/24 h, or 
both, combined with a hemoglobin value >  90 g/L, serum albumin 
level >  30 g/L, and serum calcium level <  2.61 mmol/L), Thirty- 
eight patients had stationary disease that did not respond to treatment, 
and in 20 patients the disease progressed (data were lacking for 11 
patients). Ninety-six of these patients were later given second-line 
treatment, and of these, 46 patients received third-line treatment 
because of poor response or progressive disease. Thus, at the time 
of conditioning for BMT, 18 patients were in complete remission, 
66 were in partial remission, 22 had stable disease that did not 
respond to further treatment, 14 had primary refractory disease, 25 
had progressive disease despite treatment, and 14 were in relapse 
following complete or partial remission. Data were incomplete in 
three patients.
Conditioning Treatment fo r  BMT
The conditioning for BMT was total-body irradiation (TBÏ) plus 
cyclophosphamide alone in 55 patients, TBI plus cyclophosphamide 
and melphalan in 27 patients, and TBi plus other drug combinations 
in 35 patients. Forty-five patients received high-dose chemotherapy 
without TBI. Twenty-five of these patients were conditioned with 
busulfan plus cyclophosphamide.
Prevention o f  Graft-Versus-Host Disease
Treatment for the prevention of graft-versus-host disease (GVHD} 
varied. Twenty-one different combinations of T-cell depletion, meth­
otrexate, cyclosporine, prednisone, prednisolone, and cyclophospha­
mide were used. The single most common combination was 
cyclosporine plus methotrexate, which was used in 74 patients. Other 
drug combinations without T-cell depletion were used in 33 patients. 
T-cell depletion combined with drugs was used in 41 patients and 
alone in 13 patients. In one patient, information was lacking. Evalua­
tion of GVHD was possible in 134 patients, of whom 46 received 
T-cell-depleted marrow, alone or in combination with drugs.
Statistic a I Analysis
*
Comparison of frequencies of complete remission was made with 
the conventional x 2 tcst or> when small numbers made the y 2 test 
improper, with Fisher’s exact test. Survival curves were generated 
according to the Kaplan-Meier method and were tested with the log- 
rank test. Kaplan-Meier curves were dicotomized when less than 
five patients were under observation. Multivariate survival analyses 
were made with proportional hazards regression, with all quantitative 
variables dicotomized into qualitative variables.
Table 1. Complete Remission Following BMT by Number
of Lines of Treatment Before BMT
RESULTS
No, of 
Treafmenf 
Lines Pre- 
BMT
Total 
No. of 
Patients
No. of 
Evaluated 
Patients
CR Fallowing BMT
No. of 
Patients
% of 
Total
% af 
Evaluated
Ì 64 49 36 56 73
2 50 41 19 38 46
3 46 29 16 35 55
Unknown 2 2 1
Total 162 121 72 44 60
Abbreviation: CR, complete remission.
Response to BMT
or were not yet assessable for engraftment. Of 121 pa­
tients who could be evaluated, 72 were in complete remis­
sion following BMT, o f whom 16 were already in com­
plete remission before conditioning for BMT. The median 
time from BMT to complete remission was 3 months, 
and in 90% of patients who entered complete remission, 
the monoclonal component had disappeared at 12 months 
posttransplant. However, in a small number of patients, 
the monoclonal Ig persisted for longer time periods, and 
in two patients it persisted for 36 months then disap­
peared.
The response to BMT was highly dependent on factors 
before conditioning. Forty-nine o f 64 patients who were 
on first-line treatment at the time of BMT were assessable 
for complete remission, and 36 of these 49 patients en­
tered a complete remission, while only 19 of 41 evaluated 
patients who underwent transplantation while receiving 
second-line treatment and 16 of 29 evaluated patients 
who underwent transplantation while receiving third-line 
or later treatment entered a complete remission (Table 1). 
The difference in complete remission rate between those 
who were on first-line treatment compared with those 
who were on second or later lines o f treatment was highly 
significant (JP =  .008).
The status immediately before conditioning was not 
significantly predictive for response to BMT, except for 
patients who were in complete remission before trans­
plantation (Table 2). For those who were not in complete 
remission immediately before conditioning, 24%, 36%, 
and 50%, respectively, o f the patients who had progres­
sive disease, primary refractory disease, or stable but non- 
responsive disease entered a complete remission follow­
ing BMT.
Other factors that were important predictors of re­
sponse included stage o f disease at diagnosis and patient 
sex. Irrespective of whether patients were transplanted in
Remission status posttransplant was assessable in 121 later stages of disease, those who were diagnosed in stage 
patients. Forty-one patients either died before engraftment I had a significantly higher response rate than those who
Table 2. Compiete Remission by Status at Conditioning
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Total No. of
CR Following BMT
Status at Conditioning No. of Evaluated No. of %of % of
Before BMT Patients Patients Patients Total Evaluated
CR 18 16 15 83 94
Partial remission 66 52 28 42 54
Stable disease 22 20 11 50 55
Primary refractory 14 8 5 36 63
Progressive disease 25 14 6 24 43
Relapse 14 9 Ó 43 67
Unknown 3 2 1
Total 162 121 72 44 60
were diagnosed in stage II or stage III (P <  .05) (Table 
3). IgG myeloma had a significantly poorer complete re­
mission rate than other subtypes (Table 4). Male patients 
also had a poorer response than females.
Bone Lesions
Bone lesions could be evaluated in 98 patients by roent­
genography. Patients who did not survive day 100 were 
not assessable. Twenty-two of 98 patients had a normal 
roentgenographic picture before transplantation; 17 did 
not change following transplantation, while five pro­
gressed. Twenty-three patients had minor lytic lesions or 
osteoporosis; six improved, 10 were stationary, and seven 
progressed. Fifty-three patients had major lytic lesions; 
six improved and 47 were stationaiy. Thus, in 57 of 76 
patients who had bone changes before BMT, the roent- 
genographic bone pattern did not change following BMT.
GVHD
One hundred thirty-four patients could be evaluated for 
GVHD. It was absent in 50 (37%). Forty-three had grade 
I, 29 grade II, six grade III, and six grade IV. Because 
of the many various GVHD prevention methods used, it 
was difficult to analyze any specific preventive method 
separately. However, if T-cell depletion was included in 
the preventive method, alone or together with other treat­
ment modalities, the fraction of patients who had grade
. r CR Following BMT 
Total No. of --------------------------------------
No. of Evaluated No. of % of % of
Diagnosis Patients Patients Patients Total Evaluated
IgG 80 58 27 34 47
IgA 33 25 17 52 68
Light chain 31 23 18 58 78
Other 18 15 10 56 67
Total 162 121 72 44 60
II to IV GVHD was significantly less than if no T-cell 
depletion was used (P — .02) (Table 5).
Survival and Disease-Free Survival
The overall median survival duration after BMT was 
17 months (Fig 1). The 4-year survival rate was 32% and 
the 7-year survival rate 28%. One patient has survived 
for 10 years.
Univariate Analysis
Females had significantly better survival than males (P 
= .04) (Fig 2), but there was no significant difference in 
survival between patients less than 40 years of age and 
those >  40 years (n = 55) (P =  .18).
Patients with stage I disease at diagnosis had a signifi­
cantly better survival than those diagnosed in stages II 
and III (P = .05) (Fig 3).
Patients with IgA myeloma tended to have better sur­
vival than patients with IgG myeloma (P = .08) and those 
with light-chain myeloma (P = .28) (Fig 4). There was 
no apparent difference between patients with or k -  
chain myeloma.
The level of /?2-microglobulin was measured in 45 pa­
tients at the time of diagnosis. There was a tendency 
for better survival in patients who had /32-microglobulin 
values less than 4 mg/L as compared with those who had 
a higher value (Fig 5).
Patients who had received only one line of treatment 
had significantly better survival than those who had re-
Table 3. Complete Remission Following BMT by Stage at Diagnosis
Stage at 
Diagnosis
Total 
No, of 
Patients
No, of 
Evaluated 
Patients
CR Following BMT
No. of % of % of 
Patients Total Evaluated
1 22 19 15 68 79
II 30 18 11 37 61
III 109 83 45 41 54
Unknown 1 1 1
Total 162 121 72 44 60
Table 5. T-Cell Depletion and GVHD
GVHD Prevention
Total No. 
of
Evaluated
Patients
Grade of GVHD (% of evaluated patients)
Absent 1 II III IV
T-cell depletion 
with or without 
other treatment
46 48 35 13 0 4
No T-cell depletion 88 32 31 26 7 5
Total evaluated 134 37 32 22 4 4
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Survival
Fig 1. Actuarial survival in 
162 patients who underwent a l­
logeneic BMT,
ceived three or more lines of treatment (P = .02) (Fig 
6). There was also a tendency for better survival in pa­
tients who had received only one line of treatment as 
compared with those who had received two lines of treat­
ment (P = ,24).
The status at conditioning was of importance. Patients 
who were in complete remission at the time of condition­
ing had significantly better survival than other patients (P 
= .05). However, within the groups partial remission, 
stable but nonresponsive disease, primary refractory dis-
Survival
Fig 2. Actuarial survival after 
BMT according to patient sex. 
Kaplan-Meier curves show sig­
nificantly better survival among 
females than among males (P =
.04}.
1316 GAHRTON ET AL
Survival
Fig 3. Actuarial survival after 
BMT according to stage of dis­
ease at diagnosis. Kaplan-Meler 
curves show significantly better 
survival among patients with 
stage I disease at diagnosis than 
among those with stages I! and
HI (P *  .05).
ease, and relapse or progressive disease, there was no tendency for patients who were transplanted later than 6
significant difference. months from diagnosis to do worse than those who were
The time from diagnosis to transplant was not of sig- transplanted before 6 months from diagnosis. This ten-
nificant importance for survival* However, there was a dency for poorer survival was weak, but strongest for
Fig 4. Actuarial survival after 
BMT according to myeloma sub- 
type. Kaplan-Meier curves show 
a tendency for better survival 
among patients with IgA my­
eloma than among those with 
IgG (P *= .08) or light-chain my­
eloma (P = .28).
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Fig 5. Actuarial survival after 
BMT according to /^“microglob- 
ulin level at diagnosis. There was 
a slight, but nonsignificant trend, 
toward better survival among 
patients with values < 4 mg/L 
than among those who had val-
2: 4 mg/L.ues
patients who were transplanted later than 36 months from the wide variety of regimens used made comparisons
diagnosis (JP =  . Î 8). between different types o f regimens difficult. The number
Bone marrow transplantation procedural factors of im- of patients in each treatment group was small, so differ-
portance for prognosis could not be detected. However, enees were unlikely to be detected. TBI plus cyclophos-
Survival 
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Fig 6. Actuarial survival after 
BMT according to number of lines 
of treatment regimens used pre- 
transplantation. Kaplan-Meier 
curves show significantly better 
survival among patients who re­
ceived only 1 line of treatment v 
those who received 3 lines of 
treatment (P *= .02]. There was  
also a tendency for better sur­
vival among patients who re­
ceived only I line of treatment 
v those who received 2 lines of 
treatment (not significant).
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Fig 7, Actuarial survival after 
BMT according to whether pa­
tients were in complete remis­
sion (CR) after engraftment. 
Kaplan-Meier curves show sig­
nificantly better survival among 
patients who entered CR after 
engraftment than among those 
who did not (P = .001).
phamide was the most commonly used conditioning tor, although there was a tendency for a higher risk for all 
method. There was no significant difference between this of the factors that were significant in the univariate analy-
method and busulphan plus cyclophosphamide (P = .24). sis. The strongest tendency for favorable survival in the
Although graft-versus-host prevention methods that in- multivariate analysis was female sex as opposed to male 
eluded T-cell depletion resulted in fewer patients with sex (P = .07) and being in stage I at diagnosis as opposed
GVHD grade II to IV and a greater fraction of patients to being in other stages (P = .11). Of posttreatment prog-
without GVHD, this did not translate into a trend for nostic factors, the most important adverse one was to have
better survival. acute GVHD grade III or TV (P = .0006). Most important
Postengraftment factors were also important predictors was the comparison between patients who entered a com-
of survival. Patients who entered a complete remission plete remission following BMT and those who did not.
following BMT had significantly longer survival than For fair comparison, only those patients who were not
those who engrafted, but did not enter complete remission in complete remission before BMT, but entered complete
(P = .001) (Fig 7). The median survival duration for remission following BMT, were compared with those who
patients who were in complete remission following BMT engrafted after BMT, but did not enter remission after
was 60 months, and one patient in this group had survived BMT. Even then, patients who entered complete remission
for 10 years. had significantly better survival (P = .01). The 5-year
Patients who had GVHD grade III or IV had extremely survival rate of patients who entered complete remission
poor survival. It was significantly poorer than for those was 52% and the 7-year survival rate 47% (Fig 7). 
who had grade I or II GVHD (P -  .02). There was no
significant difference between patients who had no Relapse Rate and Relapse-Free Survival
GVHD and those who had grade I or II. 
Multivariate Analysis
The relapse-free survival rate of patients who entered 
complete remission was 34% at 6 years (Fig 8). Nine 
patients are still in complete remission more than 4 years
Multivariate analysis was attempted to estimate the sig- following transplantation. The overall relapse rate was
nificance and order of each risk factor. However, the 45% at 60 months (Fig 9). There was no significant differ-
material was probably too small for a fair analysis. No ence between assessable patients who had received T-cell
single pre-BMT factor came out as a significant risk fac- depletion or no T-cell depletion.
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Relapse free 
survival
Fig 8. Actuarial relapse-free 
survival in 72 patients who en­
tered complete remission follow'* 
mg allogeneic BMT.
Causes o f Death
At the time of analysis, 57 patients were alive and 103 
had died. Two patients were lost for follow-up evaluation. 
The causes of death were mainly the same as those in
other patients with hematologic disorders who have un­
dergone BMT. The primary cause o f death was the origi­
nal disease in 27 patients, while in the others it was 
transplant-related, ie, bacterial or fungal infections in 19,
Relapse rate
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Fig 9. Relapse rate in 72 pa­
tients who underwent allogeneic
BMT.
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interstitial pneumonitis in 17, acute GVHD in 10, hemor­
rhage in seven, organ failure in six, adult respiratory dis­
tress syndrome (ARDS) in four, venooclusive disease in 
three, chronic GVHD in three, and other causes in seven.
DISCUSSION
We have previously reported that allogeneic BMT in 
multiple myeloma produces a high complete remission 
rate, with a fraction of patients entering sustained long­
term complete remission.11 Analysis of prognostic factors 
at that time demonstrated a significantly higher complete 
remission rate in patients with stage I disease at diagnosis, 
n patients who had received only one line of treatment, 
aid in those who were in complete remission before con- 
oitioning for transplantation; however, although there 
were trends for longer survival in these patients, these 
were not statistically significant. In the present study, we 
were able to demonstrate significantly higher complete 
remission rates, and also significantly better survival in 
patients who were in stage I at diagnosis, who had re­
ceived only one line of treatment before bone marrow 
transplantation, or who were in complete remission before 
conditioning as compared, respectively, with patients who 
were in later stages at diagnosis, had received two or 
more lines of treatment, or were not in complete remission 
before conditioning. In addition, we observed that females 
have a higher complete remission rate and better survival 
than males. In BMT for leukemia, the reason for a similar 
difference appears to be that results are poorer if female 
marrow is given to male recipients, than if female marrow 
is given to female recipients.12*13 A slight trend in this 
direction was seen, but it was not significant.
The age of the patient within the age bracket 23 to 59 
years was not of significant importance for outcome. 
There was only a slight trend for patients less than 40 
years to have better survival than older patients. This 
would agree with a recent study of patients with leukemia, 
which showed that the prognostic impact of age is small 
between 30 and >  50 years.14
The response rate was higher for both IgA and light- 
chain myeloma than for IgG myeloma. However, only 
IgA myeloma tended to have a better survival than IgG 
myeloma. Such a difference has generally not been noted 
with conventional chemotherapy, except in patients 
treated with combinations of interferon and melphalan.15 
In one such study, patients with IgA or Bence-Jones- 
only myeloma had a significantly better response rate and 
survival than patients with IgG myeloma.14
A limited number of patients were investigated for /?2- 
microglobulin level at diagnosis. Patients with a high /?2~ 
microglobulin level (>  4 mg/L) tended to do worse than
tfiose with /?2-microglobulin levels below this value. This 
was similar to the importance of /¡?2-microglobulin jn pa_ 
tients treated with conventional chemotherapy4,7,8 or 
ABMT.16
The importance of procedural factors for outcome is 
difficult to investigate in this heterogenously treated mate­
rial. No superiority of any conditioning regimen to the 
conventional regimen of TBI plus cyclophosphamide was 
detectable. The follow-up time of patients treated with 
busulphan plus cyclophosphamide was shorter than for 
patients treated with TBI plus cyclophosphamide or other 
chemotherapeutic agents. Thus, it is difficult to make a 
fair comparison; however, the shape of the survival curve 
suggests that busulphan plus cyclophosphamide is not su­
perior to any other treatment modality used. If anything, the 
tendency was for poorer survival, but it was not significant. 
Busulphan plus cyclophosphamide has recently been com­
pared with TBI plus cyclophosphamide in a prospective, 
randomized study of other hematologic disorders by the 
Nordic Bone Marrow Transplant Group (NBMT),17 Al­
though no significant difference in overall survival was 
found, patients with more advanced disease had a signifi­
cantly poorer survival using busulphan plus cyclophospha­
mide than TBI plus cyclophosphamide, and it appeared 
that venoocclusive disease and hemorrhagic cystitis were 
more frequent in the busulphan-plus-cyclophosphamide 
group. The combination of busulphan plus cyclophospha­
mide for BMT in myeloma has been extensively evaluated 
by the Seattle group,18 who found that, in 12 of 15 assessa­
ble myeloma patients (N =  20), a complete remission was 
obtained, with complete remission defined as disappear­
ance of the Ig assayed by immunofixation. The probability 
of survival at 3 years was 36%. As in the EBMT study, 
most patients had a relatively advanced stage of disease. 
Although this study was a phase I study that escalated the 
dosages of busulphan, it should be noted that four of 20 
patients developed venooclusive disease. This seems to 
support our view that venooclusive disease may well be 
more common following busulphan plus cyclophospha­
mide as compared with TBI plus cyclophosphamide. Of 
103 patients with myeloma who died in the present EBMT 
study, only three had venooclusive disease determined as 
the primary cause of death.
Graft-versus-host prevention methods varied and it was 
therefore difficult to analyze any particular methodology. 
With T-cell depletion, acute GVHD was absent in 48% 
of patients. Without T-cell depletion, it was absent in 
only 32%, However, the lower frequency of GVHD with 
T-cell depletion did not translate into better survival or 
result in a higher relapse rate in comparison to those who 
were not T-cell-depleted. Thus, it was not possible to
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show in this study, as has been previously shown for 
BMT in leukemias,19,20 that patients with GVHD grade I 
or II had a lower relapse rate than patients with no GVHD. 
Nor was it possible to show that T-cell depletion resulted 
in a higher relapse rate, as has previously been shown 
for chronic myelocytic leukemia.13,21,22 However, it is pos­
sible that the heterogeneity in the present study has pre­
vented the detection of such a possible graft-versus-my- 
eloma effect, which would have been abolished or 
diminished by T-cell depletion.
The most important predictor for long-term survival 
following BMT was complete remission after en- 
graftment. The difference between survival of patients 
who entered remission and patients who engrafted with 
signs of multiple myeloma was highly significant. Also, 
a substantial fraction of complete remittors are still in 
complete remission up to 10 years following transplanta­
tion. Thus, obtaining a complete remission is crucial for 
long-term survival. Persistance of myeloma cells, Igs in 
serum, or light chain in urine will probably inevitably 
result in disease progression. However, a sizeable fraction 
of patients with very poor prognostic parameters before 
transplantation survived for more than 2 years, although 
they did not enter complete remission. Thus, it is possible 
that BMT may prolong life even in a fraction of patients 
who do not enter remission following transplantation.
This prognostic factor analysis does not give conclu­
sive help in selecting patients for allogeneic BMT. Since 
the best results are obtained in females, in patients who 
are diagnosed in stage I irrespective of whether they are 
transplanted in another stage, in patients who have re­
ceived only one line of treatment, and in those who were 
in complete remission already before transplantation,
such patients appear to be reasonable candidates. How­
ever, as these groups of patients may also have relatively 
good prognosis with other treatment modalities, such as 
ABMT, with a lower initial transplantation mortality, it 
is difficult at this stage to recommend allogeneic BMT 
unreservedly for all of these patient groups. Still, it seems 
reasonable to conclude that allogeneic BMT could be 
performed at a stage when first-line treatment fails or if 
the patient is unresponsive to first-line treatment. In such 
cases, survival with chemotherapy is usually poor. Also, 
BMT can be performed not only in patients less than 40 
years of age but also in older patients, probably up to 55 
years of age. Although factors that predict poor prognosis 
with conventional chemotherapy, such as stage III multi­
ple myeloma and a high /32-microglobulin level, also pre­
dict for relatively poor prognosis with transplantation, 
some patients might be candidates for BMT, since long­
term survival is sometimes obtained. Patients with IgA 
myeloma seem to be especially good candidates for BMT.
The choice o f treatment modality in multiple myeloma 
is becoming increasingly complex. Chemotherapy, 
ABMT, and allogeneic BMT are now competing meth­
ods. Although our results indicate that allogeneic BMT 
should preferably be done early, perhaps during or after 
failure of first-line treatment, and before several lines 
of treatment, comparative studies must be performed to 
determine the value of each treatment method. Controlled, 
prospective trials are extremely difficult to perform. For 
that reason, matched-pair analysis studies, as has been 
done for comparison of BMT and chemotherapy in acute 
leukemia,23 may be more realistic to delineate factors that 
might guide selection of one or the other method. Such 
analyses are in progress.
APPENDIX
The following centers participated in the study by reporting patients to the Myeloma Registry at Huddinge Hospital Hospital: Centre 
Hospitalier Regional et Universitaire, Angers, France (M. Boasson); Hospital Clinic, Barcelona, Spain (J. Bladé, C. Rozman); Kantonspital, 
Basel, Switzerland (A. Gratwohl); Hôpital Jean Minjoz, Besançon, France (M. Flesch); Hospital San Orsola, Bologna, Italy (M. Cavo, S. 
Turn); Institut Jules Bordet, Brussels, Belgium (L, Debusscher); Cliniques Universitaires St. Luc, Brussels, Belgium (A. Ferrant); Hôpital 
Caen, Caen, France (X. Troussard); Groote Shuur Hospital, Cape Town, South Africa (P. Jacobs); Hôpital Henri Mondor, Creteil, France 
(J.-P, Vernant); Universität Düsseldorf, Düsseldorf, Germany (K. Quabeck); Ospedale di Careggi, Firenze, Italy (F. Rossi); Hôpital Cantonal 
Universitaire, Geneva, Switzerland (B. Chapuis); Ospedale San Martino, Genova, Italy (M. Van Lint); Hôpital A. Michallon, Grenoble, 
France (C. Chabannon, M. Michallet); Medical School of Hannover, Hannover, Germany (H. Link); University of Helsinki, Helsinki, Finland 
(L. Volin); Huddinge Hospital, Huddinge, Sweden (G. Gahrton, P. Ljungman); Christian-Albrechts-University, Kiel, Germany (N. Schmitz); 
University Hospital, Leiden, The Netherlands (van de Loo); Hôpital Claude Hurez, Lille, France (T. Façon); University Medical Center, 
Ljubljana, Slovenia (J. Pretnar); Royal Marsden Hospital, London, United Kingdom (P. Selby); The London Clinic, London, United Kingdom 
(P. Gravett); Royal London Hospital, London, United Kingdom (A.C. Newland); Charing Cross Hospital, London, United Kingdom (D. 
Samson); University Hospital, Lund, Sweden (B. Sallerfors); Hotel Dieu, Nantes, France (J.L. Harousseau); University Hospital, Nijmegen, 
the Netherlands (T. de Witte, A. Schattenberg); Hôpital Cochin, Paris, France (C. Belanger); Pesaro Hospital, Pesaro, Italy (G. Lucarelli); 
Hôpital du Haut Leveque, Pessac, France (J. Reif fers); S. Camillo Hospital, Roma, Italy (A. De Laurenzi); Dr Daniel Den Hoed Cancer 
Center, Rotterdam, the Netherlands (A. Hagenbeek); University Central Hospital, Turku, Finland (J. Nikoskelainen, A. Toivanen); and 
University Hospital, Utrecht, the Netherlands (L. Verdonck).
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